Antagonist Activation Measurement at the Ankle Using High-density and Bipolar Surface EMG in Chronic Hemiparesis

NCT06099132 | Completed

• 1 other identifier: CC2017
• Study Type: observational
• Target: 12
• Locations: 0 countries
• Sites: N/A

Brief Summary

In chronic hemiparesis, abnormal antagonist muscle activation in the paretic lower limb contributes to impair ambulation capacities. A biased estimate of antagonist muscle activation when using surface bipolar EMG compared with high-density (HD) EMG has been previously reported in healthy subjects. The present study compares muscles cocontraction at the paretic ankle estimated with a pair of and multi-channel surface EMG.

Conditions

Stroke; Muscle Hypertonia; Spasticity, Muscle

Outcome Measures

Primary Outcomes (1)

• Coefficient of ANtagonist activation

  The Coefficient of ANtagonist activation of 3 muscles was calculated by the ratio between the root mean square amplitude during antagonist effort and maximal agonist effort for the same muscle.

  5 seconds

Interventions

Electromyographic measurements DIAGNOSTIC_TEST

HD and bipolar EMG were assessed from gastrocnemius medialis (GM), soleus (SO) and tibialis anterior (TA) at seated position, ankle at 0°, during isometric submaximal effort and maximal effort, knee flexed (90°) and knee extended (0°)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Person with chronic hemiparesis due to a non-evolutive central nervous system lesion

You may qualify if:

• hemiparesis due to a non-evolutive central nervous system lesion
• time since lesion ≥ 6 months
• ability to walk 10 meters barefoot without any assistance
• cognitive abilities to understand the verbal instructions for the test according to the investigator's judgment
• absence of botulinum toxin injections within the last 3 months prior to enrolment

You may not qualify if:

• botulinum toxin injections within the last 3 months prior to enrolment

Sponsors & Collaborators

• Henri Mondor University Hospital: lead

MeSH Terms

Conditions

Stroke; Muscle Hypertonia; Muscle Spasticity

Condition Hierarchy (Ancestors)

Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Neuromuscular Manifestations; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Muscular Diseases; Musculoskeletal Diseases

Study Officials

• Emilie Hutin

  Hôpitaux Universitaires Henri Mondor

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director

Study Record Dates

• First Submitted: October 19, 2023
• First Posted: October 25, 2023
• Study Start: January 1, 2017
• Primary Completion: December 31, 2017
• Study Completion: December 31, 2017
• Last Updated: October 25, 2023

Record last verified: 2023-10

Data Sharing

• IPD Sharing: Will not share